Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/14/2002US20020169206 Substituted biphenyl compounds for the treatment of inflammation
11/14/2002US20020169205 Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
11/14/2002US20020169204 Use of triaqua-mu3-oxohekakis-mu-propionatotrichromium(1+), [Cr3O(O2CCH2CH3)6(H2O)3]+, as a nutritional supplement or in treatment of medical conditions
11/14/2002US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002US20020169202 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
11/14/2002US20020169201 Compounds and methods for regulating cell differentiation
11/14/2002US20020169200 Antitumor, antiinflammatory and antiarthritic agents, treating metastasis, restenosis, osteoporosis, inflammation, macular degeneration, and diabetic retinopathy
11/14/2002US20020169199 Ready-to-inject; buffer with pH of 7.2 to 4.0, a water-soluble organic solvent, an antioxidant and an agent which binds heavy metal ions
11/14/2002US20020169198 Agonists of the progesterone receptor; contraceptives, hormone replacement therapy and treating menopause symptoms
11/14/2002US20020169196 Cyclic AMP-specific phosphodiesterase inhibitors
11/14/2002US20020169195 Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathione
11/14/2002US20020169194 Treating vision defects
11/14/2002US20020169192 Peroxisome proliferator activator receptor (PPAR); amino-ethyl- phenyl derivatives
11/14/2002US20020169191 Oxazolidinone compounds and methods of preparation and use thereof
11/14/2002US20020169190 Dosing schedule of antitumor agents
11/14/2002US20020169189 Benzamide derivatives as thrombin inhibitors
11/14/2002US20020169187 Phenylazacycloalkane for treating dyskinesias, dopamine agonists and transplantation of dopamine neurons into the patient's brain
11/14/2002US20020169186 Tetrahydroquinoline derivatives as glycine antagonists
11/14/2002US20020169183 Acridines as stimulators for Fas-mediated apoptosis
11/14/2002US20020169182 Neurotrophin antagonist compositions
11/14/2002US20020169181 Arylglycinamide derivatives
11/14/2002US20020169180 Quinoline or quinazoline derivatives; antitumor agent, treating respiratory tract and gastrointestinal disorders
11/14/2002US20020169179 Treatment of ischemic brain injury
11/14/2002US20020169178 Benzothieno[3,2-c]pyridines as alpha2 antagonists
11/14/2002US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002US20020169176 Method for inhibiting retinoid skin damage
11/14/2002US20020169174 Xanthine phosphodiesterase V inhibitors
11/14/2002US20020169172 Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases
11/14/2002US20020169171 Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists
11/14/2002US20020169170 Arylpiperazines having activity at the serotonin 1A receptor
11/14/2002US20020169169 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal
11/14/2002US20020169168 Pharmaceutical formulations of ciprofloxacin
11/14/2002US20020169167 Benzimidazoles that are useful in treating sexual dysfunction
11/14/2002US20020169166 Benzimidazoles that are useful in treating sexual dysfunction
11/14/2002US20020169165 Substituted bicyclic derivatives for the treatment of abnormal cell growth
11/14/2002US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002US20020169163 1,2,3,4-tetrahydro-pyrazino(1,2-a)indole derivatives useful in treating obesity, central nerveous system diosrders, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea
11/14/2002US20020169162 Device and method for treating conditions of a joint
11/14/2002US20020169160 Sulfonamide matrix metalloproteinase inhibitors
11/14/2002US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002US20020169158 Administering to a patient a (tetrahydra-4,7,8,10 methyl-1 (chloro-1-phenyl)-6 (methoxy-4-phenyl-carbamoyl)-9 pyrido (4',3'-4,5)thieno (3,2-f)triazolo-1,24 (4,3-a) diazepine-1,4) as antiangiogenesis agent; anticarcinogenic agent
11/14/2002US20020169156 Azacyclooctane and heptane derivatives, their preparation and use in therapy
11/14/2002US20020169154 Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
11/14/2002US20020169153 Substituted aromatic compounds for treatment of antibiotic resistant infections
11/14/2002US20020169152 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
11/14/2002US20020169151 Administering to a mammal,in the absence of estrogen or an agonist, an amount of progesterone or an agonist effective to decrease vascular smooth muscle cell proliferation in the mammal
11/14/2002US20020169150 Hormone replacement therapy
11/14/2002US20020169149 Antimicrobial formulations
11/14/2002US20020169148 Use of alendronate for the prevention of osteoporosis
11/14/2002US20020169145 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
11/14/2002US20020169144 Angiogenesis inhibition
11/14/2002US20020169143 Methods and products related to low molecular weight heparin
11/14/2002US20020169142 Viscoelastics for use in middle ear surgery
11/14/2002US20020169141 Potentiates the coadministration of irinotecan
11/14/2002US20020169140 Minimising dosage required of chemotherapeutic agents for their use in antiviral, antibacterial, antiparasitic and anticancer chemotherapy; for treating neoplasms and tumours, viral, bacterial, or parasite infections
11/14/2002US20020169135 Administration of a G1 and/or S phase drug, which is preferably beta-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel
11/14/2002US20020169134 Use of substituted azetidinone compounds for the treatment of sitosterolemia
11/14/2002US20020169132 Polypeptides
11/14/2002US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002US20020169114 Formulation of boronic acid compounds
11/14/2002US20020169109 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
11/14/2002US20020169103 Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
11/14/2002US20020169102 Intranasal delivery of agents for regulating development of implanted cells in the CNS
11/14/2002US20020169101 Administering a bombesin receptor antagonist
11/14/2002US20020168740 Kinase for use in the treatment of inflammation, viral infection, cancer, sepsis, psoriasis and restenosis
11/14/2002US20020168728 Generation preferential proteins; obtain gram-negative prokaryotic cell, transform with nucleotide sequences coding protein, culture, recover protein
11/14/2002US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002US20020168711 Nucleic acids, proteins, and antibodies
11/14/2002US20020168695 Detecting cell proliferative disorder in humans; obtain tissue sample, incubate with probe, detect signal from tissue sample, signal indicates cancer
11/14/2002US20020168687 Inhibition of tau-tau-association
11/14/2002US20020168650 Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
11/14/2002US20020168633 Nucleotide fragment of the 23s rna of the genus chlamydia, use as a probe, primer, and in a reagent and a detection procedure
11/14/2002US20020168436 Decursinol or derivative thereof as analgesic agent
11/14/2002US20020168433 Plant extracts; mixture of isoflavones, lignan, saponin, catechin and benzoic acid
11/14/2002US20020168428 Methods and compositions for reducing sympathomimetic-induced side effects
11/14/2002US20020168427 Plant extract
11/14/2002US20020168424 Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
11/14/2002US20020168421 Mixture of aminobenzoic acid, hydroxybenzoic acid, cysteine, methionine, selenium, lithium bromide and plant extracts
11/14/2002US20020168414 Rapid dehydration of proteins
11/14/2002US20020168413 Microstructure grains; fine particle size
11/14/2002US20020168412 Topical drug preparations
11/14/2002US20020168411 Spill resistant pharmaceutical system
11/14/2002US20020168405 Novel Method of treatment
11/14/2002US20020168403 Mixture of monoamine oxidase inhibitor and additive substance; reducing withdrawal
11/14/2002US20020168402 Microprecipitation method for preparing submicron suspensions
11/14/2002US20020168399 Applicator and method for applying lanolin to a sore nipple
11/14/2002US20020168397 Antiallergens, antiinflammatory agents; oral administering
11/14/2002US20020168395 Uniform crystal structure
11/14/2002US20020168389 Oil in water emulsion; skin disorders
11/14/2002US20020168386 Instant granules and process for their formulation
11/14/2002US20020168385 Adeno-associated virus vector for boosting immunogenicity of cells
11/14/2002US20020168371 Process for reducing antibody response against xenografts
11/14/2002US20020168369 Treatment of skin conditions
11/14/2002US20020168366 Administering a binding agent capable of binding platelets binding platelets to the binding agent to form captured platelets, inducing activation of the captured platelets and forming a thrombus, which provides therapeutic benefit
11/14/2002US20020168361 An isolated protein comprising a soluble CD97 alpha subunit, and soluble subunit is selected from the group alpha 1, alpha 2, and alpha 3, originate as proprotein with beta subunit
11/14/2002US20020168360 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
11/14/2002US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002US20020168355 Cationic liposome delivery of taxanes to angiogenic blood vessels
11/14/2002US20020168350 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
11/14/2002US20020168344 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
1 ... 5650 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 ... 7860